2016, Number 620
<< Back Next >>
Rev Med Cos Cen 2016; 73 (620)
Acromegalia
Núñez DN
Language: Spanish
References: 15
Page: 485-490
PDF size: 201.04 Kb.
ABSTRACT
Acromegaly is a disease
product of an excessive amount
of growth hormone (GH)
which is caused mainly by a
tumor in the pituitary gland.
These high concentrations
of GH level causes changes
in bone, muscle and adipose
tissue, which is manifested as
prognathism, frontal bossing
and acral growth, besides heart
and metabolic alterations.
Diagnosis is performed by
measuring GH after a glucose
load, and must also measure
IGF -1 values. The first line
treatment is transphenoidal
surgery for tumor resection,
if this is the cause, you can
with somatostatin analogues,
GH receptor antagonists or
dopamine agonists, and as
a last resort you can send
radiotherapy. In pregnant
patients it is recommended to
discontinue medical treatment,
and prescribe it in cases which
is desired to control the size of
the tumor or the patient present
major headache.
REFERENCES
Anderson M. GH excess: Diagnosis and medical therapy. Eur J Endocrinol. 2013 Nov 29; 170 (1): R31-R41.
Capatina C, Wass JA. 60 Years of Neuroendocrinology, Acromegaly. J Endocrinol. 2015 Aug; 226 (2): T141-T160.
Cheng S, Al-Agha R, Araujo P, Serri O, Asa S, Ezzat S. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly. PLoS One. 2013 Sep; 9 (8): e73543.
Dias M, Boguszewski C, Gadelha M, Kasuki L, Musolino N, Vieira J, Abucham J. Acromegaly and pregnancy: a prospective study. Eur J Endocrinol. 2013 Dec 21; 170 (2): 301-310.
Dreval A, Trigolosova I, Misnikova I, Kovalyova Y, Tishenina R, Barsukov I, Vinogradova A, Wolffenbuttel B. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect. 2014 Apr 29; 3 (2): 93-98.
Guistina A, Chanson P, Kleinberg D, Bronstein M, Clemmons D, Klibanski A, van del Lely A, Strasburger C, Lamberts S, Ho K, Casanueva F, Melmed S. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014 Apr; 10 (4): 243-248.
Katznelson L, Laws E, Melmed S, Molitch M, Hassa Murad M, Utz A, Wass J. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99 (11): 3933-3951.
Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. International Journal of Endocrinol. 2012; 2: 1-10.
Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009 Nov; 119 (11): 3189-3202.
Melmed S, Colao A, Barkan A, Molitch M, Grossman A, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance M, Ho K, Guistina A. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009 May; 94 (5): 1509- 1517.
Perel C, Echin M. Acromegalia y enfermedad cardiovascular. Insuf Card. 2011; 6 (4): 188-202.
Thanabalasingha G, Grossman A. Acromegaly: beyond surgery. Indian J Endocrinol Metab. 2013 Jul; 17 (4): 563-367.
Trainer P. ACROSTUDY: the first 5 years. Eur J Endocrinol. 2009 Nov; 161 Suppl 1: S19- S24
Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 2013 Jun 7; 169 (1): 99- 108.
Vilar L, Valenzuela A, Rigobeiro- Oliveria A, Gómez C, Pantoja D. Multiple facets in the control of acromegaly. Pituitary. 2014 Jan; 17 Supple 1: S11- S17.
Full text